Immune-Onc Therapeutics, Inc. news

• IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors
• Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the dosing of the f

• Company announces completion of Phase 1 dose escalation ahead of schedule for IO-108, a first-in-class antibody targeting LILRB2 (ILT4)
• Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China.<

• IO-108 is the first LILRB2-targeting antibody administered to Chinese patients
• Implementation of IO-108 program in China initiates Immune-Onc’s global clinical development plan; Phase 1 trial has completed dose escalation in the U.S. in solid tumor patients

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the fir

• Multicenter Phase 1 study to evaluate IO-108 as both monotherapy and in combination with pembrolizumab in China
• Represents the first LILRB2-targeting antibody with IND clearance in China and the company’s fourth IND globally
• A Phase 1 trial evaluating IO-108 in patients with advanced solid tumors is currently enrolling in the U.S.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage canc

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts. Charlene Liao, Ph.D., chief executive officer of Immune-Onc and Paul Woodard, M.D., chief medical